Teleflex (NYSE:TFX) Given Overweight Rating at Piper Sandler

Teleflex (NYSE:TFX)‘s stock had its “overweight” rating reissued by research analysts at Piper Sandler in a note issued to investors on Friday,Benzinga reports. They presently have a $169.00 price objective on the medical technology company’s stock, up from their previous price objective of $160.00. Piper Sandler’s target price would suggest a potential upside of 24.81% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Needham & Company LLC lifted their target price on shares of Teleflex from $147.00 to $159.00 and gave the company a “buy” rating in a report on Friday, July 31st. Wells Fargo & Company upped their price objective on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. BMO Capital Markets initiated coverage on Teleflex in a research report on Wednesday, July 8th. They set an “outperform” rating and a $159.00 target price on the stock. Raymond James Financial reiterated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $149.80.

Teleflex Stock Performance

NYSE TFX traded down $3.48 during trading hours on Friday, reaching $135.41. The stock had a trading volume of 207,256 shares, compared to its average volume of 796,840. Teleflex has a 52-week low of $100.18 and a 52-week high of $145.00. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. The stock has a market cap of $5.99 billion, a P/E ratio of -5.93, a price-to-earnings-growth ratio of 1.02 and a beta of 0.81. The stock has a fifty day moving average of $131.61 and a 200 day moving average of $122.46.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.28 by $0.48. The company had revenue of $570.33 million for the quarter, compared to analyst estimates of $559.59 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The firm’s revenue was up 28.9% on a year-over-year basis. During the same period in the prior year, the company earned $3.73 earnings per share. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Sell-side analysts predict that Teleflex will post 6.7 earnings per share for the current year.

Institutional Investors Weigh In On Teleflex

A number of hedge funds have recently modified their holdings of the business. Hsbc Holdings PLC grew its holdings in Teleflex by 4.7% in the 1st quarter. Hsbc Holdings PLC now owns 1,861 shares of the medical technology company’s stock worth $222,000 after buying an additional 84 shares in the last quarter. Banque Cantonale Vaudoise raised its stake in shares of Teleflex by 82.5% during the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Teleflex by 40.5% in the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock worth $48,000 after purchasing an additional 113 shares during the period. UMB Bank n.a. lifted its holdings in Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after purchasing an additional 113 shares during the period. Finally, Maryland State Retirement & Pension System grew its position in Teleflex by 1.5% in the 4th quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock valued at $1,056,000 after buying an additional 129 shares in the last quarter. 95.62% of the stock is currently owned by institutional investors and hedge funds.

More Teleflex News

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex reported second-quarter revenue of $570.3 million, up 28.9% year over year and above the $559.6 million consensus estimate. Adjusted EPS was $1.76, beating expectations of $1.28. Teleflex Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management provided fiscal 2026 adjusted EPS guidance of $6.90 to $7.20, above the analyst consensus of $6.70. Full-year revenue guidance of approximately $2.3 billion was broadly in line with expectations, suggesting earnings execution remains a strength. Teleflex Reports Second Quarter Results and Outlook
• Neutral Sentiment: Teleflex declared a quarterly dividend of $0.34 per share, payable September 30 to shareholders of record August 14. The dividend represents an annualized payout of $1.36 per share and an approximately 1% yield.
• Negative Sentiment: GAAP diluted EPS from continuing operations fell to $0.96 from $1.54 in the prior-year quarter, while adjusted EPS declined from $3.73 a year earlier despite the headline beat. This weaker year-over-year earnings trend may be weighing on investor sentiment. Teleflex Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue growth was only 4.7% on a pro forma adjusted constant-currency basis, considerably below the reported 28.9% increase. With revenue guidance merely matching consensus, investors may be focused on the pace of underlying growth rather than the acquisition- or accounting-related headline increase.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.